North America Spinal Muscular Atrophy Treatment Market Size, Share & Industry Trends Analysis Report By Type (Type 1, Type 2, Type 3 and Type 4), By Route of Administration, By Treatment Type (Drug and Gene Therapy), By Drug Type, By Country and Growth Fo

North America Spinal Muscular Atrophy Treatment Market Size, Share & Industry Trends Analysis Report By Type (Type 1, Type 2, Type 3 and Type 4), By Route of Administration, By Treatment Type (Drug and Gene Therapy), By Drug Type, By Country and Growth Forecast, 2022 - 2028

The North America Spinal Muscular Atrophy Treatment Market would witness market growth of 16.9% CAGR during the forecast period (2022-2028).

This genetic disorder kills specific nerve cells present in the spinal cord and brain called motor neurons. Motor neurons regulate skeletal muscle actions such as walking, swallowing, speaking, and breathing as well as movement in the legs, face, arms, chest, throat, and tongue. SMA comes in four different forms.

The most prevalent and serious form of SMA is type 1 and it is also known as Werdnig-Hoffmann illness or infantile-onset SMA. It typically manifests before the age of six months. SMA's Type 2 is a middle variant. Usually, between the ages of 6 and 18 months, symptoms become apparent. Children can sit unaided but cannot stand or walk unassisted.

SMA's Type 3 variant is further milder than the Type 2. It also goes by the name Kugelberg-Welander illness, and it appears to be muscular dystrophy after the age of 18 months. Children can walk on their own, but they can have trouble running, climbing stairs, or getting up from a chair. Type 4 is quite uncommon and it typically begins in adolescence, resulting in modest motor disability.

In this region, the SMA treatment are widely adopted because of its developed economy, rising health care costs, rising incidence of disorders linked to a sedentary lifestyle, and high acceptance of technologically advanced products. There are many uncommon diseases for which there is no FDA-approved medication. The treatment adoption in North America is further boosted by American reimbursement rules, particularly for the management of rare disorders like SMA.

The US market dominated the North America Spinal Muscular Atrophy Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4,222 million by 2028. The Canada market is poised to grow at a CAGR of 19.5% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 18.5% during (2022 - 2028).

Based on Type, the market is segmented into Type 1, Type 2, Type 3 and Type 4. Based on Route of Administration, the market is segmented into Injection and Oral. Based on Treatment Type, the market is segmented into Drug and Gene Therapy. Based on Drug Type, the market is segmented into Spinraza, Zolgensma (AVXS-101), Evrysdi and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

Scope of the Study

Market Segments covered in the Report:

By Type

• Type 1
• Type 2
• Type 3
• Type 4

By Route of Administration

• Injection
• Oral

By Treatment Type

• Drug
• Spinraza
• Zolgensma (AVXS-101)
• Evrysdi
• Others
• Gene Therapy

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• Biogen, Inc.
• Novartis AG
• Ionis Pharmaceuticals, Inc.
• PTC Therapeutics, Inc.
• NMD Pharma A/S
• Scholar Rock, Inc. (Scholar Rock Holding Corporation)
• Cytokinetics, Inc.
• Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.)
• Astellas Pharma, Inc.
• F. Hoffmann-La Roche Ltd. (Genentech, Inc.)

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free